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Abstract
Background: Erythropoiesis is a highly regulated and well-characterized developmental process responsible for providing
the oxygen transport system of the body. However, few of the mechanisms involved in this process have been elucidated.
Checkpoint Kinase 1 (Chk1) is best known for its role in the cell cycle and DNA damage pathways, and it has been shown to
play a part in several pathways which when disrupted can lead to anemia.
Methodology/Principal Findings: Here, we show that haploinsufficiency of Chk1 results in 30% of mice developing anemia
within the first year of life. The anemic Chk1+/2 mice exhibit distorted spleen and bone marrow architecture, and abnormal
erythroid progenitors. Furthermore, Chk1+/2 erythroid progenitors exhibit an increase in spontaneous DNA damage foci
and improper contractile actin ring formation resulting in aberrant enucleation during erythropoiesis. A decrease in Chk1
RNA has also been observed in patients with refractory anemia with excess blasts, further supporting a role for Chk1 in
clinical anemia.
Conclusions/Significance: Clinical trials of Chk1 inhibitors are currently underway to treat cancer, and thus it will be
important to track the effects of these drugs on red blood cell development over an extended period. Our results support a
role for Chk1 in maintaining the balance between erythroid progenitors and enucleated erythroid cells during
differentiation. We show disruptions in Chk1 levels can lead to anemia.
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Introduction
In a recent study, we used microarrays to examine gene
expression differences in several hematopoietic cell types and
found the cell cycle regulator Checkpoint Kinase 1 homolog (Chk1)t ob e
highly expressed in hematopoietic stem cells, T-cells, and erythroid
progenitors as compared to the other cell types (Figure 1A) [1].
Because Chk1 deficiency has been shown previously to lead to a
block in T-cell differentiation [2], we considered the possibility
Chk1 may play a role in erythropoiesis. Erythroid cell development
is a highly regulated multi-stage process resulting in the production
of red blood cells (RBCs). Great strides in understanding this
process have been made; however many aspects of the path from a
hematopoietic progenitor to a mature red blood cell (RBC) remain
unclear. The role of erythropoietin in early erythroid differenti-
ation has been well studied. Erythropoietin is the best understood
factor promoting erythropoiesis, and is already used in the clinical
setting [3]. Yet until recently, the latter phases of erythroid
development, i.e. the processes responsible for enucleation and the
final stages of differentiation were poorly, if at all, characterized
[4,5,6,7].
A wide range of biological pathways have now been shown to
contribute to the end-stages of red blood cell (RBC) development
beginning with the essential role macrophages play in the
enucleation process by engulfing the newly expelled nuclei [6].
Recent and innovative studies done by Ji et. al. have illustrated the
roles of two Rho GTPases (Rac1 and Rac2) and mDia2 in the final
steps of red blood cell development. These experiments demon-
strated the consequences of failing to properly regulate actin
filaments necessary for contractile actin ring (CAR) formation,
which is required for erythroblast enucleation to generate mature
RBCs [8]. Additional studies have shown the importance of
mitochondrial autophagy in the maturation of red blood cells [4].
A role for the retinoblastoma protein (Rb) in erythropoiesis has
also been demonstrated, where Rb loss causes a defect in proper
RBC differentiation resulting from defects in enucleation and the
biosynthesis of mitochondria [5,9].
Chk1 is an evolutionarily conserved serine/threonine protein
kinase with a known role in genome maintenance and DNA
damage response. Chk1 is required for embryonic development
and in adult tissues haploinsufficient phenotypes have been
observed including increased DNA damage and cell cycle
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suppressor [10]. More recently Chk1’s role has expanded into
regulating Tousled-like kinases for chromatin remodeling [11],
centrosome- and spindle assembly checkpoints [12,13] and the
repression of transcription of the cell cycle proteins cyclin B and
Cdk1 [14,15]. Moreover, we have shown Chk1 plays a vital role in
chromosome segregation and cytokinesis durning normal cell
division [16]. Thus, Chk1 acts as a critical cell cycle regulator both
in the presence and absence of DNA damage.
The human homolog (CHK1) was shown recently in a stressed
environment to be necessary for the monoubiquitination of
FANCD2, a gene which, when mutated, results in Fanconi
anaemia (FA) and is involved in the FA/BRCA pathway [17,18].
Furthermore, Chk1 was demonstrated to be necessary for the
differentiation of the chronic myelogenous leukemia cell line K562
into erythrocytes after induction with Ara-C [19]. Overall, while
Chk1 is directly or indirectly involved in a diverse set of cellular
processes many of its specific roles in development and cell
maintenance remain to be uncovered. To determine the function
of Chk1 in erythropoiesis, we took advantage of a Chk1+/2 mouse
(since homozygous nulls are early embryonic lethal) created by the
Elledge lab [20]. Here, we demonstrate an increased incidence of
anemia in the Chk1+/2 mice associated with extreme splenomeg-
aly in the affected animals. Disruption of enucleation was observed
in the Chk1+/2 mice, possibly resulting in an increase in erythroid
progenitors to compensate. Furthermore, these Chk1+/2 ery-
throid progenitors exhibited a marked increase in spontaneous
DNA damage foci and aberrant CAR formation during RBC
differentiation. Thus, this study has uncovered a new role for Chk1
during erythropoiesis and indicates that Chk1 inhibition can
contribute to anemia.
Results
Chk1 haploinsufficiency disrupts cellular architecture of
erythropoietic tissues
We previously used microarray gene expression analysis to
identify gene expression differences throughout the hematopoietic
cell system. Chk1 expression was observed in three hematopoietic
populations, namely hematopoietic stem cells, activated T-cells,
and erythroid progenitors (Figure 1A). As defects in T-cell
differentiation had already been reported [2], we investigated the
effects of losing a Chk1 allele on erythroid differentiation. Mice
heterozygous for Chk1 exhibit lower levels of Chk1 protein in their
spleens (data not shown), which in mice is a major hematopoietic
organ. We observed several Chk1 heterozygous mice with
splenomegaly and sudden death at ,26 weeks of age
(Figure 1B & 1C). Finally, when the Chk1+/2 bone marrow
cells were plated in Methocult supporting the growth of erythroid
colonies we saw a decrease in the number of BFU-E colonies from
Chk1+/2 marrow compared to WT (Figure 1D). However,
when cells were plated in Methocult supporting the growth of all
hematopoietic colonies the Chk1+/2 cells performed comparably
to WT cells (data not shown). We were intrigued by this
Figure 1. Chk1 is expressed in erythroid progenitor cells. (A) Expression profile of Chk1 in the hematopoietic cell types from a previous study
[1]. Erythrocytes, granulocytes, and LT-HSCs were isolated from WBM. Erythroid Progenitors were Ter-119
+, CD3
2,CD4
2,CD8
2,Mac-1
2,Gr-1
2, and
B220. LT-HSCs were side-population (SP)
+, Sca-1
+, c-Kit
+, and Lin
2 (Mac-1, Gr-1, Ter119, B220, CD4, CD8) (B) Gross morphology of spleens from a WT
and Chk1 mouse are drastically different. (C) Spleen weights of WT and anemic Chk1+/2. (D.) 100,000 WBM cells were plated in Methocult specific for
erythroid colony formation. BFU-E and CFU-E were counted 6 days after plating and a lack of BFU-E formation was observed from the Chk1+/2 cells.
doi:10.1371/journal.pone.0008581.g001
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background were believed to be phenotypically normal [20].
The influence of genetic background in laboratory mouse models
has a significant impact on the expected phenotype varying from
its viability to behavior. Numerous studies using various mouse
models have demonstrated that phenotypic noise can suppress or
worsen lethal phenotypes among various genetic backgrounds.
Many examples of such mouse models have been widely published
such as TGF-b1 –deficient mouse models. Backcrossing of mixed
background of TGF-b1-deficient mice to a C57Bl/6 background
results in 100% embryonic lethality whereas in a mixed
background it is only 50%. This clearly demonstrates the
‘‘modifier effect’’ within various genetic backgrounds in laboratory
mouse models that can influence the phenotypic outcome and also
variations in the penetrance of the phenotype [21].To identify the
cause of the splenomegaly, we performed histopathology of spleens
removed from age-matched Chk1+/2 and wild type (WT) adult
mice. Histologic examination of Chk1+/2 spleens using hematox-
ylin and eosin staining revealed a range of phenotypes from a mild
expansion of red pulp area to an overwhelming disruption of
splenic architecture. In the most severe cases, sections of the spleen
showed complete loss of normal architecture with markedly
expanded red pulp and minimal white pulp. A prominent
histocytic infiltrate with evidence of erythrophagocytosis is present,
and numerous apoptotic bodies are identifiable (Figure 2A). The
histocytes, or tissue macrophages, are necessary to engulf apoptotic
cells or cell debris and we suspect their incursion into the
hematopoietic tissue is a result of the unproductive erythropoiesis
and not the cause of the anemia. We used both Ter119, a
canonical erythrocyte-specific marker, and F4/80, a macrophage-
specific marker, to perform immunohistochemistry on spleen tissue
sections from these Chk1+/2 and WT mice. A remarkable
increase in both Ter119 and F4/80 positive staining was observed
in the Chk1+/2 spleen sections when compared to sections from
WT counterparts (Figure 2A & 2B). In summary, affected
spleens demonstrate disrupted architecture suggestive of an
expanded pool of erythroid precursors with accompanying
erythrophagocytosis of defective cells.
Since bone marrow serves as the primary site for red blood cell
production, we also examined the bone marrow of Chk1+/2 mice.
Histopathology of the sternum from Chk1+/2 mice showed near-
complete loss of normal hematopoietic elements, replaced almost
Figure 2. Chk1+/2 mice show a breakdown of hematopoietic tissue structure with age. (A) H&E stained WT and Chk1+/2 spleen sections
at 56and 406magnification and images scaled at 50 mm. Disruption of spleen architecture is plainly visible. Also shown are sections of spleen from a
52-week-old WT and anemic Chk1+/2 mouse stained with Ter-119 (HPR, brown, 56) or F4/80 (HPR, brown, 406) and counterstained with
hematoxylin. Chk1+/2 mice show a breakdown in spleen architecture and a massive increase in histiocytes. (B) WT and Chk1+/2 spleens stained with
F4/80 under 606magnification and images scaled at 20 mm. (C) H&E sections (206) of sternum from a WT and Chk1+/2 mouse showing a loss of
bone marrow architecture with a colossal histiocyte invasion. F4/80 (HPR, brown, 406) stained sternum sections shows an overwhelming increase in
histiocytes compared to WT.
doi:10.1371/journal.pone.0008581.g002
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similar to that seen in the spleen. Scattered remaining hemato-
poietic elements show tri-lineage maturation (Figure 2C). This
indicates that Chk1 haploinsufficiency can lead to serious
disruptions of erythropoietic organs such as bone marrow and
spleen in mice.
Chk1 haploinsufficiency causes anemia in adult mice
Since Chk1+/2 mice exhibit splenic erythroid imbalance and
bone marrow failure, we investigated whether Chk1 heterozygous
mice developed anemia. Studies have shown that chronic
erythrocyte depletion in the bone marrow and spleen can cause
an impaired stress response and trigger anemia in mice [22]. To
conduct these studies, we carefully monitored a large cohort of age-
matched WT (n=24) and Chk1+/2 mice (n=34) from 26 weeks of
age. The cohort was subjected to complete blood count (CBC)
analysis periodically to screen for anemia. Our analysis identified an
approximately 30% incidence of severe anemia (decrease in RBC
number and hemoglobin count) in Chk1+/2 mice within 52 weeks
of age as compared to no cases of anemiainWT miceover the same
time period. Interestingly, while the mean cell volume (MCV) of the
Chk1+/2 erythroid cells was only slightly increased, the mean
corpuscular hemoglobin (MCH) and mean corpuscular hemoglobin
concentration (MCHC) in these cells was more than tripled
indicating the development of a hyperchromic anemia. In addition,
we observed significant decreases in platelet counts (Figure 3).
However,wedidnotobserve asignificantchangeinwhite bloodcell
number or differential counts between anemic Chk1+/2 and WT
mice. In addition, the severity of anemia did not appear to correlate
with increased spleen size in all cases. These results suggest anemia
as the most likely cause for the sudden death of Chk1+/2 mice
observed in our mouse colony.
Figure 3. A significant number of Chk1+/2 mice become anemic with age. (A) Kaplan-Meier plot showing the incidence of anemia in the
Chk1+/2 mice compared to WT mice. A log-rank (Mantel-Cox) test was used to measure significance (p,0.05). Complete blood counts were done on
52-week-old WT and anemic Chk1+/2 mice and significance was established by a student’s t-test. (B) White blood counts (WBC), (C) platelet counts,
and (D) red blood cell parameters (red blood cell counts, (RBC), hemoglobin (Hgb), mean corpuscular volume (MCV), mean corpuscular hemoglobin
(MCH), and mean corpuscular hemoglobin concentration (MCHC) are shown. A student’s t-test was used to determine significance; an asterisk
indicates a p,0.05.
doi:10.1371/journal.pone.0008581.g003
Chk1 in Erythropoiesis
PLoS ONE | www.plosone.org 4 January 2010 | Volume 5 | Issue 1 | e8581Miscoordinated erythroid differentiation in Chk1
haploinsufficient mice
To understand why Chk1+/2 mice develop anemia despite
their splenic expansion and increasing erythropoiesis, we exam-
ined erythroid progenitors of anemic Chk1+/2 mice and aged
matched WT mice. We used immunostaining with Ter119 and
CD71 to identify and quantitatively measure the erythroid
progenitors in the hematopoietic tissue of anemic Chk1+/2 mice
(Figure 4A) [22,23]. The Ter119/CD71 immunostaining
identifies four cell populations during erythropoiesis, from least
differentiated proerythroblasts to more differentiated orthrochro-
matophilic erythroblasts, and finally giving rise to reticulocytes by
enucleation [22,23]. We observed striking differences between the
numbers of erythroid progenitors in the whole bone marrow of
WT and anemic Chk1+/2 mice. The assay revealed a significant
increase in the absolute number of early erythroblasts at stage I
and II compared to the WT (Figure 4B). However, there was no
significant difference between the stage III cells of Chk1+/2 and
WT mice. A slight increase at stage IV Ter119
high CD71
low
erythroblasts was also observed in Chk1+/2 mice compared to
WT (Figure 4B). In addition, we examined the Meg-Erythroid
progenitor (MEP) in WT and Chk1+/2 mice using established
markers by flow cytometry, and found a ,2-fold increase of these
progenitors (Figure 4B). The increased spleen size and the
decrease in the number of viable cells within the spleen may be
due to a buildup of apoptotic or malformed cells awaiting
engulfment by histocytes. The expansion of early erythroid
progenitors and the increased cell death observed in the spleen
suggests a block or miscoordination of differentiation at the early
erythroblast stage in Chk1+/2 mice resulting in an increased
number of erythroid cells unable to progress through maturation.
Chk1+/2 erythroid progenitors show a massive increase
in spontaneous DNA damage foci
To understand the cause for aberrant enucleation in Chk1+/2
erythroid progenitors during erythropoiesis, we used immuno-
staining of erythroid progenitors with well-studied DNA damage
markers pcH2AX and 53BP1. Typically, the DNA damage
response pathway is activated in response to DNA double strand
breaks(DSBs). This leads to phosphorylation of the histone variant
cH2AX by ataxia telangiectasia mutated (ATM) and Rad-3
related ATR kinases, which causes pcH2AX to localize to the site
of DSBs. Several other mediator proteins in the DNA damage
response pathway such as e.g. MDC1, 53BP1, and BRCA1, are
also phosphorylated by ATM/ATR and recruited to the sites of
DNA damage [24]. Thus, a complex of damage sensing and repair
proteins are assembled at the site of DNA strand breaks to initiate
DNA repair and cell cycle arrest through the activation of
downstream checkpoint kinases [25].
Previous studies from our laboratory, demonstrated that
proliferating mammary epithelial cells in a conditional Chk1
heterozygous mouse model showed miscoordinated cell cycle
events and spontaneous DNA damage foci formation [10]. Since
mammalian erythropoiesis involves proliferation, chromatin
Figure 4. Anemic Chk1+/2 mice exhibit severe defects in several stages of erythropoiesis. (A) Representative flow cytometry plots
showing CD71 and Ter-119 staining used to separate the stages of erythropoiesis for WT and Chk1+/2 mice. (B) The MEP and stages I–IV of
erythropoiesis were analyzed via flow cytometry from the whole bone marrow of anemic Chk1+/2 mice and 52-week-old WT mice. A student’s t-test
was used to determine significance; an asterisk indicates a p,0.05.
doi:10.1371/journal.pone.0008581.g004
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mature RBCs, we hypothesized that Chk1+/2 erythroblasts also
might accumulate DNA damage during RBC differentiation. As
expected, we observed co-localization of pcH2AX and 53BP1 at
the site of DNA damage foci in the nucleus of all the four Chk1+/
2 erythroid populations, from least differentiated stage I to more
differentiated stage IV erythroblasts isolated from the bone
marrow of young non-anemic Chk1+/2 mice (Figure 5,
Table 1). Thus, a marked increase in DNA damage foci was
observed in both proliferating and differentiating Chk1+/2
erythroid progenitors during erythropoiesis, whereas WT ery-
throid cells did not display DNA damage foci. These results
demonstrate that haploinsufficiency of Chk1 in the proliferating
erythroblasts resulted in the accumulation of DNA damage, which
possibly caused a block or miscoordinated erythroid differentiation
and fewer mature red blood cells.
Erythroid progenitors undergo abnormal enucleation
during erythropoiesis in Chk1 haploinsufficient mice
To further investigate the misregulation of erythroid differen-
tiation, we took advantage of a previously developed technique to
study enucleation [6]. Briefly, hematopoietic cells are stained with
two DNA dyes, one that is impermeable to cell membranes and
another which can pass through membranes. Then flow cytometry
is used to separate out nucleated cells (only stained by the cell-
permeable dye), and enucleated cells (unstained). In our studies,
cells were not only examined by size, but by Ter-119 positivity
before examining their enucleation status (Figure 6A). The P1
gated (small) cells should almost entirely consist of RBCs with most
cells being enucleated and a few cells having their nucleus. The P2
gated (large) cells should be immature erythrocytes with their
nuclei still intact. We examined young (10 weeks old) non-anemic
mice to discover if a disruption in erythroid differentiation could
be observed before anemia occurred in these mice.
Surprisingly upon examining the P1 gated cells, the young and
non-anemic Chk1+/2 mice exhibited a decrease in enucleated
cells, and an increase in nucleated cells as compared to WT mice.
The P2 gated Chk1+/2 cells showed a significant decrease in
nucleated cells and an increase in enucleated cells (Figure 6B).
The increase in inappropriately large enucleated erythroid cells
and the decrease in small properly enucleated cells in the Chk1+/2
mice support the idea of miscoordinated erythroid differentiation.
In the Chk1+/2 mice, a failure of the erythroid progenitors to
successfully and appropriately eject their nuclei may result in an
influx of histiocytes to dispose of the failed cells.
Chk1+/2 erythroid progenitors fail to enucleate during
erythropoiesis due to improper CAR formation
The results from the enucleation assay also revealed that
Chk1+/2 erythroid progenitors failed to properly eject their
nucleus during the enucleation process. Mammalian erythroid
cells enucleate via asymmetric cell division involving extrusion of
the condensed nucleus enclosed within a plasma membrane.
Numerous studies show that asymmetric cell division in mammals
involves cytokinetic components, wherein formation of contractile
actin ring at the midbody provides the required momentum for
abscission of dividing daughter cells [26]. Past studies have shown
that actin filaments also play a critical role in the formation of
contractile actin ring (CAR) at the boundary of the cytoplasm of
budding reticulocyte and nucleus of enucleating cell [27]. Recent
studies have shown CAR formation is indispensable for enucle-
ation and Chk1 appears to interact with the cytokinetic machinery
responsible for separating cells during cell division [8,16,28].
Therefore, to examine the kinetics and dynamics of actin
filaments during CAR formation as shown by Ji et al., we
immunostained the four populations of young Chk1+/2 and WT
erythroid cells during erythropoiesis with fluorescently labeled
Phallodin, an actin binding protein. Interestingly, we observed
aberrant CAR formation in the Chk1+/2 erythroid cells at stage
IV as compared to the CAR observed at stage IV in WT erythroid
cells. Moreover, the least differentiated proerythroblasts of Chk1+/
2 mice at stage I also displayed less intense actin staining as
compared to the stage I proerythroblasts from WT mice
(Figure 6C, Table 2). Therefore, these results provide an
explanation for the abnormal increase of nucleated P1 gated
Chk1+/2 erythroid cells as compared to WT observed using
the enucleation assay. Thus, these results demonstrate that
Chk1 haploinsufficiency may result in improper CAR form-
ation, presumably leading to unsuccessful enculeation during
erythropoiesis.
Chk1 expression in human erythroid progenitors and
clinical anemia
To determine whether Chk1 was also expressed in human
erythroid precursors, we obtained cDNA from each stage of
erythroid development isolated from human bone marrow and
used real time PCR to examine the levels of Chk1 expression. We
found Chk1 to be highly expressed in stage I progenitors when
compared to stage IV cells, and to steadily decrease as the cells
differentiated (Figure 7A). A similar pattern of expression was
observed in the mouse erythroid progenitors (data not shown).
Finally, we wanted to determine if a decrease in Chk1 expression
has previously been observed in human anemias. For this we did
an in silico search for Chk1 expression in anemias by using GEO
Profiles (http://www.ncbi.nlm.nih.gov/geo/). When we examined
Chk1 expression in this data set, we found it significantly decreased
in patients suffering from myelodysplastic syndromes with
refractory anemia with blasts [29] (Figure 7B). These data
indicate a possible role for CHK1 in human erythropoiesis and as a
contributor to clinical anemias.
Discussion
The results presented here show that Chk1 plays a role in red
blood cell formation. A loss of one Chk1 allele greatly increases the
chances of developing anemia in mice and illustrates the
importance of maintaining the correct levels of Chk1 in erythroid
progenitor cells. Moreover, a decrease in Chk1 RNA has been
observed in patients with refractory anemia with excess blasts,
further supporting an important role for Chk1 status in clinical
anemia [29]. Anemia can occur due to excessive blood loss, death
of blood cells, or ineffective blood cell production [30]. Our
findings support a role for Chk1 haploinsufficiency in the latter
method of anemia induction.
In many ways the phenotype of the Chk1+/2 erythroid cells are
reminiscent of the erythroid-specific retinoblastoma protein (Rb)
knockout cells. This mouse model shows an increase in Ter119+
CD71
high cells and a decrease in enucleated cells [5,9,31], similar
to our Chk1 mutant mice. However, in the erythroid-specific Rb2/
2 mice, their spleens show an expansion of the red pulp, but not
the complete breakdown of splenic architecture observed in the
more severely affected Chk1+/2 mice. In addition, erythroid-
specific Rb2/2 cells exhibited severe micronucleation and DNA
damage, thus affecting enucleation during erythropoiesis [32].
Similarly, we have also observed a marked increase in spontaneous
DNA damage foci formation shown by co-localization of DNA
damage markers pH2AX and 53BP1 in the nucleus of
Chk1 in Erythropoiesis
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erythropoiesis. These studies support the idea that critical cell
cycle regulators and checkpoint proteins such as Rb and Chk1 also
play a role in erythroblast enucleation to generate terminally
differentiated mature RBCs. Inappropriate expression or regula-
tion of these cell cycle regulators may have a severe impact on
Figure 5. Chk1+/2 erythroid progenitors show a marked increase in spontaneous DNA damage foci. Progenitors from stages I–IV were
sorted from WT and Chk1+/2 mice and immunostained with DNA damage markers 53BP1(green), pH2AX(red) and DAPI(blue). The Chk1+/2
erythroid progenitors from stages I–IV showed dramatic increase and co-localization of 53BP1 and pH2AX at the site of spontaneous DNA damage
and double strand break in the nucleus, resulting in miscoordination of enucleation during erythropoiesis compared to WT counterparts at 606
magnification and images scaled at 20 mm.
doi:10.1371/journal.pone.0008581.g005
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erythroblasts.
Apoptosis has been shown to play a key role in erythropoiesis
and Chk1 has recently been shown to be cleaved by caspases
resulting in a hyperactive form of Chk1 [33,34]. Caspases have
been shown to play key roles in the balance between cell death and
fully differentiated red blood cells during erythropoiesis [7,35].
Furthermore, when siRNA against caspase-3 was expressed in
CD34+ progenitor cells, they failed to differentiate into reticulo-
cytes at the same rate as cells transfected with a control siRNA
[35] resulting in an increase in the early stage erythroid cells. This
phenotype is very similar to what we see in the Chk1+/2 mice,
making this another attractive pathway for future studies.
Finally, studies have shown that erythroid cells evict their nucleus
via asymmetric cytokinesis and apparently healthy Chk1+/2 mice
already have small but significant disruptions in their ability to
properly enucleate erythroid cells (Figure 6B). Our results indicate
that improper CAR formation in Chk1+/2 erythroid cells during
late stages of erythropoiesis, provides one of the explanations for
unsuccessful enucleation. It is possible that inappropriate regulation
of pathways controlling cytokinesis caused by decreased Chk1 levels
might contribute to the improper enucleation of the erythroid cells.
The increase in hematopoietic stress of the Chk1+/2 mice likely
leads to signals being sent to the hematopoietic progenitors to
increase the number of MEPs in an attempt to compensate for the
reductionof normal RBCs. Thisin turn mayincrease the amount of
failed erythroid cells in the Chk1+/2 mice possibly resulting in
anemia and an even greater influx of histiocytes, which ultimately
take over the hematopoietic tissues. Future studies will be required
to determine if interactions between Chk1 and the recently identified
adaptor protein mDia2 during CAR formation play any role in
enucleation during erythropoiesis.
Ultimately, apparently healthy Chk1+/2 mice have small but
significant disruptions in their ability to properly produce RBCs, as
well as additional defects (Figure S1), yet only 30% of Chk1+/2
mice develop anemia. This suggests the existence of a compen-
satory mechanism that allows the majority of mice to escape full
blown anemia. However, not all mice can fully exploit this
mechanism, and in these cases yet undefined additional insults to
the hematopoietic progenitors appear to occur leading to an
unrecoverable defect. Disruptions of DNA repair caused by the
decreased dose of Chk1 could easily lead to additional ‘‘hits’’ in the
genome resulting in frank anemia [10]. Thus, we believe Chk1
haploinsufficiency causes a slight defect in normal erythropoiesis
and in the presence of stress. e.g. such as infection, this defect is
exacerbated, leading to anemia. Many of Chk1’s wide-ranging
roles in cellular functions can either directly or indirectly affect
proteins and processes already shown to play key roles in
erythropoiesis, and it is most likely a combinatorial effect of
deficiencies, which individually may exert a relatively minor
phenotype, yet together result in anemia in 30% of these mice.
Elucidation of the role Chk1 plays in erythropoiesis may lead to a
better understanding of its possible role in clinically relevant
anemias, and will be important in designing therapeutic studies in
cancer patients using the new generation of Chk1 inhibitors
entering clinical trials.
Materials and Methods
Mouse colony and aging study
Previously published Chk1+/2 mice [20] on a mixed genetic
background C57Bl/66129Sv/J were back-crossed for six gener-
ations with C57Bl/6 mice (Harlan). Genotyping was carried out
by PCR, using mouse tail DNA and specific primers designed
against the Chk1 WT and null allele. The presence of Chk1 null
allele was confirmed by using a primer set against the neomycin
gene of the following sequence, NeoF (59-GAT CGG CCA TTG
AAC AAG ATG G-39) and NeoR (59-CCT GAT GCT CTT
CGT CCA GAT C-39), respectively.
For the aging study, a large cohort of age-matched Chk1+/2
and WT mice were pooled at 26 weeks of age and a complete
blood count (CBC) was carried out periodically, approximately
every 4 weeks. Mice were bled retro-orbitally with EDTA hand-
coated capillary tubes and 60 mL of blood was obtained. CBCs
were then carried out with either an Abbott Cell-Dyn 3500 or a
Drew Scientific Hemavet 950. The mice were sacrificed with an
end point of either 52 weeks of age or when they developed
anemia (an RBC count below normal range). Mice used for all
these studies were euthanized according to IACUC approved
animal protocol guidelines.
Flow cytometry of erythroid progenitors
Whole bone marrow and spleen was isolated, made into single
cell suspensions, and counted with a Vi-Cell (Beckman Coulter)
and trypan blue exclusion was used to calculate viability. Cells
were taken to a concentration of 100 million cells per mL. They
were then stained on ice with various antibody cocktails to identify
each progenitor compartment as previously described [22,36] (all
antibodies were obtained from BD PharMingen, San Diego, CA
and used at a concentration of 1:100 unless otherwise indicated).
MEP were stained with biotin Lineage markers (gr-1, ter-119,
CD4, CD8, CD3, B220, CD19), IL7ra PE-Cy7 (eBioscience), Sca-
1 FITC, and cKit PE, CD34 Alexa Fluora 647(at
1:50)(eBioscience), and CD16/32 Alexa Fluor 700 (at
1:50)(eBioscience) for 20 min. Cells were then spun down,
resuspended, and stained with strepavidin-Pacific Blue(1:50) for
20 min. Stage I–IV erythroid cells were stained with Ter-119-APC
and CD71-PE for 20 min. Finally, cells were then spun down,
resuspended in a propidium iodide solution and analysis was
accomplished on live cells with an LSRII (Becton Dickinson,
Franklin Lakes, NJ).
Human erythroid progenitors were isolated in a fashion similar
to mouse cells, however glycophorin A was used instead of Ter-
119 since there is no known human Ter-119. Ter-119 is associated
with cell surface glycophorin A, a well-known erythroid marker for
humans, making it a reasonable substitute [37].
Table 1. Chk1+/2 erythroid cells exhibit DNA damage foci.
Genotype Erythroid Stage Foci/Cells % Cells with Foci
Wt I 1/201 0.5
II 0/205 0.0
III 2/200 1.0
IV 3/210 1.4
Foci/Cells % Cells with Foci
Chk1+/2 I 199/200 99.5
II 200/201 99.5
III 191/209 91.4
IV 187/200 93.5
Erythroid cells (Stages I–IV) were isolated via FACS and stained with the DNA
damage markers pcH2AX and 53BP1. At least 200 cells per stage were then
examined for the formation of DNA damage foci and WT and Chk1+/2 mice
were then compared. A significant increase in DNA damage foci was observed
in the Chk1+/2 cells (student’s t-test. p,0.001).
doi:10.1371/journal.pone.0008581.t001
Chk1 in Erythropoiesis
PLoS ONE | www.plosone.org 8 January 2010 | Volume 5 | Issue 1 | e8581Tissue preparation and immunohistochemistry
Spleen and sternum from Chk1 heterozygous and WT adult
mice were isolated and fixed overnight in 4% paraformaldehyde
(PFA) and stored in 70% ethanol at 4uC before subjecting to
further processing. The specimens were paraffin-embedded and
5 mm serial sections were cut on Probe on Plus slides (Fisher
Scientific). For histology, these sections were deparaffinized with
xylene, and rehydrated with varying concentration of ethanol.
Figure 6. Chk1+/2 mice show a disruption in enucleation of erythrocytes in the bone marrow. (A) Representative flow cytometry plot of
enucleation assay used. Syto 16 is cell permeable, whereas Sytox Blue is cell impermeable, thus the two dyes in tandem allow the separation of
enucleated and nucleated erythrocytes [6]. Low FSC Ter-119+ cells or high FSC Ter-119+ were examined for the percentage of nucleated or
enucleated cells. Low FSC (small) cells are the more mature erythrocytes, while high FSC (large) cells are the more immature erythrocytes. (B) The P1
gated cells, which should almost entirely consist of RBCs, have fewer properly enucleated erythrocytes with an increase in cells having their nuclei in
Chk1+/2 whole bone marrow. The P2 gated cells, the majority of which should be immature erythrocytes with their nuclei still intact show a decrease
in nucleated cells with a concurrent increase in enucleated cells in the Chk1+/2 whole bone marrow. (C) Progenitors from stages I–IV were sorted
from WT and Chk1+/2 mice and immunostained with Alexa-flour 594 Phalloidin(red) and DAPI(blue). The WT erythroid progenitors from stages I–IV
show dynamics of actin filaments during CAR in erythropoiesis. WT erythroid progenitors in Stages III and IV display formation of CAR (yellow arrows).
Aberrant CAR formation (yellow arrows) is observed in stages III and IV Chk1+/2 erythroid progenitors at 606magnification and images scaled at
20 mm.
doi:10.1371/journal.pone.0008581.g006
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rinse in acid ethanol. Finally, the sections were immersed in eosin
stain for 45 sec and then dehydrated with ethanol and xylene
overnight. They were mounted with Permount and air-dried
completely before imaging under Zeiss Axioplan II upright
microscope.
For immunohistochemistry, similar deparaffinization was per-
formed with xylene and ethanol and followed by heat-induced
antigen retrieval using 10 mM sodium citrate by boiling for
20 min. All washes were performed with 16PBS throughout the
procedure unless otherwise stated. Sections were then incubated
with the respective antibodies Ter119 (1:2000) or F4/80 (1:10,000)
in 5% BSA and 0.5% blocking buffer. Sections were washed and
incubated with anti-mouse (Oncogene Research) or anti-rat
(Oncogene Research) secondary antibodies diluted 1:1000 in 5%
BSA and 0.5% blocking buffer for 1 hour at RT. Vectastain Elite
ABC and diaminobenzidine (DAB) substrate kits were used to
detect immunoperoxidase staining according to the manufactur-
er’s instructions (Vector Laboratories). Slides were counterstained
with hematoxylin for 30 sec, dehydrated, and mounted using
Permount. The sections were air-dried completely and imaged
using a Zeiss Axioplan II upright microscope. All pictures were
scaled to size for figures with Adobe Illustrator.
Immunostaining and microscopy. After isolation by
FACS, erythroid cells from Chk1+/2 and WT mice bone
marrow were applied on to the slides by placing a drop of
10,000 cells on each slide and allowing them to air dry to the slide.
The cells were fixed with 4%PFA, permeabilized with 0.5%
Triton X-100 and incubated with 5% goat serum (Sigma, St.
Louis, MO) mixed with primary antibody at dilutions of anti-
pcH2AX (Upstate, CA) 1:500 and anti-53BP1(Bethyl laboratories,
CA) at 4C overnight. All the cells were washed 3 times with 16
PBS for 10 min and incubated with 5% goat serum mixed with
respective fluorochrome-conjugated secondary antibodies or Alexa
flour 594 Phalloidin(Invitrogen) at 1:1500 for 1 hr at RT. Cells are
washed 5 times for 15 min and counterstained with Vectashield
4,6-diamidino-2-phenylindole (DAPI) to visualize DNA.
Microscopic analysis was performed using an Olympus BX50
Fluoresence microscope (Applied Precision, Washington) at 606
magnification using 262 bin and images were processed using
Spot software and Adobe Photoshop.
Erythroid Colony Formation
Whole bone marrow (WBM) was collected from WT and
Chk1+/2miceand100,000 WBM cellswereplatedonto Methocult
M3436 (Stem Cell Technologies), which drives and supports
formation of BFU-E and CFU-E colonies only, in six well plates.
Six days after plating cells, colonies were counted and typed.
Real-Time PCR
RNA was isolated from 1610
5 cells (except for HSCs which was
from 2.5–5610
4 cells), using the RNAqeuous kit (Ambion, Austin,
TX, USA), treated with DNAseI, and precipitated with phenol:-
chloroform:isoamyl alcohol. RNA was quantified using a Nano-
drop and 30 ng of RNA was used for each RT-PCR reaction. RT-
PCR was performed with Superscript II (Invitrogen). Taqman
master mix and CHK1 taqman probe (Applied Biosystems) was
used for the real-time PCR reactions and 18s was used as an
internal control. All reactions were run on an ABI prism 7900HT
according to manufacturer’s protocol (Applied Biosystems).
Enucleation Assay
Whole bone marrow cells were isolated, made into single cell
suspensions, and stained on ice with Ter119-APC (BD PharMin-
gen, San Diego, CA (1:100)) for 20 min. Cells were then spun
down and resuspended with 10 mM Syto16 (Invitrogen) and 8 mM
Sytox Blue (Invitrogen) in HBBS with 10% FBS. Cells were
allowed to sit at room temperature for 20 min; they were then
analyzed with an LSRII (Becton Dickinson, Franklin Lakes, NJ).
Data Mining
An in silico search for Chk1 expression in anemias by using GEO
Profiles (http://www.ncbi.nlm.nih.gov/geo/). GEO DataSets
were searched for the key words anemia and human via the
NCBI website. The results were further filtered to select for studies
using hematopoietic progenitors and examining types of anemia.
Studies utilizing samples from transplant patients, cancer patients,
or malaria patients were discarded. Finally, the normalized
expression data from the GEO profile was shown and a Z-test
was used to test for differences.
Statistical Analysis
All statistical analyses was carried out with GraphPad Prism
version 5.00 (GraphPad Software, San Diego California USA,
Table 2. Chk1+/2 show defective CAR formation.
Total Cells
per type
Wt Cells w/
defective CAR
Chk1+/2 Cells w/
defective CAR
Fischer’s
Exact test
Stage I 300 0 10 P=0.0017
Stage IV 300 4 59 P,0.0001
Total 600 4 69 P,0.0001
Erythroid cells (Stage I and IV) were examined for defective CAR formation by
immunohistiochemistry. Significant differences were calculated by Fisher’s
exact test.
doi:10.1371/journal.pone.0008581.t002
Figure 7. Chk1 expression in human erythroid progenitors and
anemia patients. (A) Taqman real-time PCR was used to examine the
expression levels of Chk1 in human erythroid progenitors and 18s was
used as an internal control (n=3). (B) A decrease in Chk1 levels (one
probe) was observed in patients (individual patients are represented as
dots and the graph) with refractory anemia with blasts when compared
to healthy individuals (Z-test, p,0.05; GEO DataSets ID=GDS2118; Affy
probe ID=238075_at) [29]. GEO DataSets were searched for the key
words anemia and human via the NCBI website (http://www.ncbi.nlm.
nih.gov/sites/entrez?db=gds). The results were further filtered to select
for studies using hematopoietic progenitors and examining types of
anemia. Studies utilizing samples from transplant patients, cancer
patients, or malaria patients were discarded. Only one study met these
criteria.
doi:10.1371/journal.pone.0008581.g007
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Kaplan-Meier method and the p value was calculated by the log-
rank (Mantel-Cox) test. All other p values reported are derived by
a student’s t-test unless otherwise indicated. Microsoft Excel was
used for the performance of Z-test.
Supporting Information
Figure S1 Non-anemic Chk1+/2 mice at 52 weeks show
differences form WT mice. Data collected from the non-anemic
Chk1+ show differences in the numbers of progenitors of these
mice when compared to WT or anemic Chk1+/2 mice. However,
WBC, RBC, HGB, HCT, and platelet counts in the non-anemic
Chk1+/2 mice are the same as WT mice. (A) In both anemic and
non-anemic Chk1+/2 mice the numbers of MEP (CD342
CD16/322 cKit+ Sca12 Lin2 Il7ra2) are elevated. However, in
the non-anemic Chk1+/2 the numbers of GMP (CD34+ CD16/
32+ cKit+ Sca12 Lin2 Il7ra2) and CMP (CD34+ CD16/322
cKit+ Sca12 Lin2 Il7ra2) are also increased, whereas in the
anemic Chk1+/2 the numbers of CMP are similar to WT and the
numbers of GMP are decreased when compared to WT. (B) The
non-anemic Chk1+/2 mice show a similar increase in the
numbers of erythroid cells in Stages I, II, and IV as anemic
Chk1+/2 mice. However, the numbers of each stage of erythroid
progenitors are not significantly increased when compared to WT
erythroid progenitor numbers.
Found at: doi:10.1371/journal.pone.0008581.s001 (0.43 MB TIF)
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